Factors associated with immunotherapy selection in patients with advanced melanoma.
Immunotherapy
; 10(16): 1361-1369, 2018 11.
Article
en En
| MEDLINE
| ID: mdl-30407098
ABSTRACT
AIM:
To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma. MATERIALS &METHODS:
Total of 12 academic and satellite clinics contributed to this study. Descriptive and logistic regression analyses were conducted to explore associations between clinical characteristics and treatment choice.Results:
Total of 400 patients were included 200 PEMBRO and 200 IPI+NIVO. Patients were significantly more likely to receive PEMBRO versus IPI+NIVO if they had poorer Eastern Cooperative Oncology Group score, 2-4 versus 0-1 (odds ratio [OR] 6.6; 95% CI 3.0-14.7), if they were PD-L1 positive (OR 4.5; 95% CI 1.9-10.4) or had BRAF wild-type tumor (OR 2.2; 95% CI 1.4-3.6).CONCLUSION:
Patient factors are significantly associated with treatment selection in advanced melanoma. Outcomes comparisons should take this into consideration.Palabras clave
Texto completo:
1
Colección:
01-internacional
Asunto principal:
Neoplasias Cutáneas
/
Anticuerpos Monoclonales Humanizados
/
Ipilimumab
/
Nivolumab
/
Inmunoterapia
/
Melanoma
Tipo de estudio:
Clinical_trials
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Immunotherapy
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Año:
2018
Tipo del documento:
Article
País de afiliación:
Estados Unidos